Company intelligence / Profile preview
Mestag Therapeutics
Saffron Walden, England, United Kingdommestagtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Mestag Therapeutics develops first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer and inflammatory diseases. Its lead program MST‑0300, a bispecific LTBR agonist antibody, aims to enhance anti-tumor immunity by promoting tertiary lymphoid structure formation in solid tumors. Another key program, M402, targets stromal checkpoints to suppress pathological immune activation in inflammatory conditions like RA and IBD. The company also uses its proprietary RAFT platform for novel target discovery and has established major pharma collaborations with MSD/Merck & Co., Janssen/J&J, and VIB. As of early/mid‑2024 the pipeline remains preclinical but advancing toward clinical entry.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesSingle domain antibodies / Nanobodies®
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Janssen Biotech Inc./Johnson & Johnson Innovation – JJDC Inc.: Target discovery/collaboration/licensing agreement for novel inflammatory disease targets [3][5].MSD/Merck & Co., Inc.: License/research collaboration using the RAFT platform for new drug targets; deal value up to $1.9B [8][9].VIB Research Institute Belgium: Exclusive rights/license for a panel of nanobodies against an undisclosed oncology target [5].
Beyond the preview
Go deeper on Mestag Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mestag Therapeutics.